Enzon Pharmaceuticals, Inc (ENZN)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Andrew D. Rackear
Employees:
0
20 COMMERCE DRIVE, SUITE 135, CRANFORD, NJ 07016
732-980-4500

Enzon Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the provision of licensing arrangements. It also involve in selling marketed drug products namely: PegIntron, Sylatron, Macugen and CIMZIA. The company was founded by Abraham Abuchowski on September 17, 1981 and is headquartered in Cranford, NJ.

Data derived from most recent annual or quarterly report
Market Cap 12.691 Million Shares Outstanding74.215 Million Avg 30-day Volume 79.024 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.15
Price to Revenue31.4986 Debt to Equity0.0 EBITDA-33.382 Million
Price to Book Value2.6665 Operating Margin-358.9646 Enterprise Value217.946 Million
Current Ratio7.516 EPS Growth0.721 Quick Ratio6.953
1 Yr BETA 52-week High/Low 0.0 / Profit Margin-363.205
Operating Cash Flow Growth-45.7097 Altman Z-Score13.1882 Free Cash Flow to Firm -55.319 Million
View SEC Filings from ENZN instead.

View recent insider trading info

Funds Holding ENZN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ENZN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

COUCHMAN JONATHAN

COUCHMAN FAMILY FUND

XSTELOS CORP.

MYREXIS, INC.

  • 10% Owner
7,743,954 2021-08-13 1

READ RANDOLPH C

  • Director
100,450 2020-11-16 1

BLEZNICK JORDAN

  • Director
100,000 2020-11-13 1

ICAHN CARL C

  • 10% Owner
39,277 2020-10-09 0

COUCHMAN JONATHAN

COUCHMAN FAMILY FUND

XSTELOS CORP.

MYREXIS, INC.

HARPER BRIAN JAMES

HARPER ASSET MANAGEMENT LLC

PEARCE MICHAEL COOPER

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
9,441,648 2020-08-24 0

MYREXIS, INC.

  • SEE FOOTNOTE 1
250 2020-03-18 1

COUCHMAN JONATHAN

COUCHMAN FAMILY FUND

XSTELOS CORP.

  • 10% Owner
5,750,930 2020-03-13 0

RACKEAR ANDREW D. CEO AND SECRETARY

  • Officer
0 2016-03-31 0

FEINSTEIN RICHARD L VP-FINANCE AND PFO

  • Officer
0 2013-12-13 0

CHRISTODORO JONATHAN

  • Director
0 2013-10-07 0

KOSTAS ODYSSEAS D

  • Director
0 2013-09-25 0

MCNEALEY JENNIFER ISACOFF

  • Director
0 2013-09-25 0

LEBUHN ROBERT

  • Director
42,189 2013-09-17 0

BUCHBINDER ABY VP, CLINICAL DEVELOPMENT

  • Officer
79,246 2013-01-23 0

CONOVER CHARLES SVP, R&D PROGRAM MANAGEMENT

  • Officer
74,793 2013-01-23 0

SALISBURY ROBERT C

  • Director
0 2013-01-02 0

DENNER ALEXANDER J

  • Director
0 2013-01-02 0

MULLIGAN RICHARD

  • Director
0 2013-01-02 0

DEUEL THOMAS

  • Director
0 2013-01-02 0

YOUNG RICHARD A

  • Director
0 2013-01-02 0

HEBARD GEORGE INTERIM PEO AND INTERIM COO

  • Officer
  • Director
43,237 2012-11-07 0

DALY TIMOTHY VP, CONTROLLER AND PAO

  • Officer
8,000 2012-03-28 0

STANCIC ANA EXECUTIVE VP, COO, PEO, CFO

  • Officer
70,000 2012-01-17 0

GREENBERGER LEE M VP, RESEARCH

  • Officer
36,146 2012-01-17 0

DEL CAMPO RALPH COO AND PRINC. EXEC. OFFICER

  • Officer
204,633 2011-09-15 0

DAVIT PAUL STEPHEN EXEC. VICE PRES. HR

  • Officer
109,314 2011-07-01 0

HORAK IVAN D EVP, R&D, CSO

  • Officer
138,476 2011-04-03 0

OGDEN MARK L ACTING VP OF FIN & PRIN FO

  • Officer
4,000 2011-02-28 0

CLASSON ROLF A

  • Director
0 2011-01-03 0

MICATI VICTOR P

  • Director
50,625 2010-07-01 0

TOOMAN CRAIG A EXEC VP FINANCE, CFO

  • Officer
160,480 2010-06-18 0

LEVY HAROLD J

  • Director
166,535 2010-02-18 0

BUCHALTER JEFFREY H CEO & PRESIDENT

  • Officer
  • Director
529,259 2010-01-27 0

IRIDIAN ASSET MANAGEMENT LLC/CT

  • 10% Owner
0 2009-07-23 0

ANDO GORAN

  • Director
40,409 2009-07-02 0

RENFRO PHILLIP M

  • Director
25,973 2008-11-14 0

GELTOSKY JOHN

  • Director
18,760 2008-07-01 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ENZON PHARMACEUTICALS INC ENZN 2021-10-25 22:15:03 UTC -1.485 1.555 100000
ENZON PHARMACEUTICALS INC ENZN 2021-10-25 21:45:03 UTC -1.485 1.555 100000
ENZON PHARMACEUTICALS INC ENZN 2021-10-25 21:15:03 UTC -1.485 1.555 100000
ENZON PHARMACEUTICALS INC ENZN 2021-10-25 20:45:03 UTC -1.485 1.555 100000
ENZON PHARMACEUTICALS INC ENZN 2021-10-25 20:15:03 UTC -1.485 1.555 100000
ENZON PHARMACEUTICALS INC ENZN 2021-10-25 19:45:04 UTC -1.485 1.555 100000
ENZON PHARMACEUTICALS INC ENZN 2021-10-25 19:15:03 UTC -1.485 1.555 100000
ENZON PHARMACEUTICALS INC ENZN 2021-10-25 18:45:02 UTC -1.485 1.555 100000
ENZON PHARMACEUTICALS INC ENZN 2021-10-25 18:15:03 UTC -1.485 1.555 100000
ENZON PHARMACEUTICALS INC ENZN 2021-10-25 17:45:03 UTC -1.485 1.555 100000
ENZON PHARMACEUTICALS INC ENZN 2021-10-25 17:15:03 UTC -1.485 1.555 100000
ENZON PHARMACEUTICALS INC ENZN 2021-10-25 16:45:02 UTC -1.485 1.555 100000
ENZON PHARMACEUTICALS INC ENZN 2021-10-25 16:15:03 UTC -1.485 1.555 100000
ENZON PHARMACEUTICALS INC ENZN 2021-10-25 15:45:03 UTC -1.485 1.555 100000
ENZON PHARMACEUTICALS INC ENZN 2021-10-25 15:15:03 UTC -1.485 1.555 100000
ENZON PHARMACEUTICALS INC ENZN 2021-10-25 14:45:02 UTC -1.485 1.555 100000
ENZON PHARMACEUTICALS INC ENZN 2021-10-25 14:15:03 UTC -1.485 1.555 100000
ENZON PHARMACEUTICALS INC ENZN 2021-10-25 13:45:03 UTC -1.485 1.555 100000
ENZON PHARMACEUTICALS INC ENZN 2021-10-25 13:15:03 UTC -1.485 1.555 100000
ENZON PHARMACEUTICALS INC ENZN 2021-10-25 12:45:04 UTC -1.485 1.555 100000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments